GB201810668D0 - New compounds - Google Patents

New compounds

Info

Publication number
GB201810668D0
GB201810668D0 GBGB1810668.2A GB201810668A GB201810668D0 GB 201810668 D0 GB201810668 D0 GB 201810668D0 GB 201810668 A GB201810668 A GB 201810668A GB 201810668 D0 GB201810668 D0 GB 201810668D0
Authority
GB
United Kingdom
Prior art keywords
new compounds
compounds
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1810668.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alzecure Pharma AB
Original Assignee
Stiftelsen Alzecure
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stiftelsen Alzecure filed Critical Stiftelsen Alzecure
Priority to GBGB1810668.2A priority Critical patent/GB201810668D0/en
Publication of GB201810668D0 publication Critical patent/GB201810668D0/en
Priority to KR1020217000575A priority patent/KR20210024531A/ko
Priority to ES19739692T priority patent/ES2935183T3/es
Priority to CA3104237A priority patent/CA3104237A1/en
Priority to JP2020570716A priority patent/JP7510358B2/ja
Priority to US17/255,642 priority patent/US11840524B2/en
Priority to CN201980045116.8A priority patent/CN112513032B/zh
Priority to EP19739692.2A priority patent/EP3814335B1/en
Priority to PCT/GB2019/051853 priority patent/WO2020002950A1/en
Priority to BR112020026619-1A priority patent/BR112020026619A2/pt
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB1810668.2A 2018-06-28 2018-06-28 New compounds Ceased GB201810668D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB1810668.2A GB201810668D0 (en) 2018-06-28 2018-06-28 New compounds
BR112020026619-1A BR112020026619A2 (pt) 2018-06-28 2019-06-28 Composto, método para tratar e/ou prevenir uma doença que apresenta sinalização prejudicada de neurotrofinas e/ou outros fatores trópicos, uso de um composto, produto de combinação, kit de partes, e, processo para a preparação de um composto
JP2020570716A JP7510358B2 (ja) 2018-06-28 2019-06-28 Ｔｒｋ受容体の調節剤としての４－置換フェニル－１，３，５－トリアジン誘導体
ES19739692T ES2935183T3 (es) 2018-06-28 2019-06-28 Derivados de fenil-1,3,5-triazina 4-sustituidos como moduladores de los receptores TRK
CA3104237A CA3104237A1 (en) 2018-06-28 2019-06-28 4-substituted phenyl-1,3,5-triazine derivatives as modulators of trk receptors
KR1020217000575A KR20210024531A (ko) 2018-06-28 2019-06-28 Trk 수용체의 조절제로서의 4-치환된 페닐-1,3,5-트리아진 유도체
US17/255,642 US11840524B2 (en) 2018-06-28 2019-06-28 4-substituted phenyl-1,3,5-triazine derivatives as modulators of TrK receptors
CN201980045116.8A CN112513032B (zh) 2018-06-28 2019-06-28 作为trk受体的调节剂的4-取代的苯基-1,3,5-三嗪衍生物
EP19739692.2A EP3814335B1 (en) 2018-06-28 2019-06-28 4-substituted phenyl-1,3,5-triazine derivatives as modulators of trk receptors
PCT/GB2019/051853 WO2020002950A1 (en) 2018-06-28 2019-06-28 4-substituted phenyl-1,3,5-triazine derivatives as modulators of trk receptors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1810668.2A GB201810668D0 (en) 2018-06-28 2018-06-28 New compounds

Publications (1)

Publication Number Publication Date
GB201810668D0 true GB201810668D0 (en) 2018-08-15

Family

ID=63143731

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1810668.2A Ceased GB201810668D0 (en) 2018-06-28 2018-06-28 New compounds

Country Status (10)

Country Link
US (1) US11840524B2 (https=)
EP (1) EP3814335B1 (https=)
JP (1) JP7510358B2 (https=)
KR (1) KR20210024531A (https=)
CN (1) CN112513032B (https=)
BR (1) BR112020026619A2 (https=)
CA (1) CA3104237A1 (https=)
ES (1) ES2935183T3 (https=)
GB (1) GB201810668D0 (https=)
WO (1) WO2020002950A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52415A (fr) 2018-02-26 2021-01-06 AlzeCure Pharma AB Dérivés de triazine pour le traitement de maladies associées à des neurotrophines
GB201912404D0 (en) * 2019-08-29 2019-10-16 AlzeCure Pharma AB New compounds
AU2021283892A1 (en) * 2020-06-03 2023-02-02 Dana-Farber Cancer Institute, Inc. Inhibitors of transcriptional enhanced associate domain (TEAD) and uses thereof
WO2025232990A1 (en) 2024-05-09 2025-11-13 AlzeCure Pharma AB Triazinone derivatives for use in the treatment of inflammation

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2246109A1 (de) 1972-09-20 1974-03-28 Bayer Ag 1-(4-phenoxy-phenyl)-1,3,5-triazinderivate, ein verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2313721A1 (de) 1973-03-20 1974-10-03 Bayer Ag Neue 1-phenylsubstituierte 1,3,5triazine, verfahren zu ihrer herstellung, sowie ihre verwendung als arzneimittel
DE2413722C3 (de) * 1974-03-21 1982-04-08 Bayer Ag, 5090 Leverkusen Neue 1-(4-Phenoxy-phenyl)-1,3,5-triazin-Derivate, ein Verfahren zu ihrer Herstellung sowie ihre Anwendung als Arzneimittel
DE2718799A1 (de) 1977-04-27 1978-11-09 Bayer Ag 1-(4-phenoxy-phenyl)-1,3,5-triazin- derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel und wachstumsfoerderer
CA1185974A (en) 1981-12-03 1985-04-23 Adolf Parg 1,3,5-triazinones and their use for controlling undesirable plant growth
DE3314739A1 (de) 1983-04-23 1984-10-25 Bayer Ag, 5090 Leverkusen 1-(4-(4-(fluoralkylmethylthio- oder -sulfinyl- oder -sulfonyl-)phenoxy) phenyl)-1,3,5-triazin-2,4,6(1h,3h,5h)-trione, verfahren zu ihrer herstellung und ihre verwendung als coccidiosemittel
DE3408768A1 (de) 1984-03-09 1985-09-12 Bayer Ag, 5090 Leverkusen Immunstimulierende mittel
DE3516632A1 (de) 1985-05-09 1986-11-13 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 1,3,5-triazintrionen
DE3516631A1 (de) 1985-05-09 1986-11-13 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 3-methyl-1,3,5-triazintrionen
DE3703105A1 (de) 1987-02-03 1988-08-11 Bayer Ag Mittel gegen protozoen bei insekten
DE3810080A1 (de) 1988-03-25 1989-10-05 Bayer Ag Trisubstituierte 1,3,5-triazin-2,4,6-trione
DE3814323A1 (de) 1988-04-28 1989-11-09 Hoechst Ag Wasserloesliche zubereitungen von coccidiostatica
US4933341A (en) 1988-10-08 1990-06-12 Bayer Aktiengesellschaft Substituted 1,3,5-triazinetriones, for use against parasitic protozoa
DE4000624A1 (de) 1990-01-11 1991-07-18 Bayer Ag Fungizide verwendung von trisubstituierten 1,3,5-triazin-2,4,6-trionen, neue trisubstituierte 1,3,5-triazin-2,4,6-trione und verfahren zu ihrer herstellung
DE4329096A1 (de) 1993-08-30 1995-03-02 Bayer Ag Heterocyclylbenzoheterocyclen
CZ146296A3 (en) 1995-06-02 1997-04-16 American Cyanamid Co 3-(3-aryloxyphenyl)-1-(substituted methyl)-s-triazine-2,4,6-oxo or thiotriones, process of their preparation and herbicidal agents
US5519133A (en) 1995-06-02 1996-05-21 American Cyanamid Co. 3-(3-aryloxyphenyl)-1-(substituted methyl)-s-triazine-2,4,6-oxo or thiotrione herbicidal agents
US5726126A (en) * 1995-06-02 1998-03-10 American Cyanamid Company 1-(3-heterocyclyphenyl)-S-triazine-2,6,6-oxo or thiotrione herbicidal agents
US5604180A (en) 1995-06-02 1997-02-18 Crews, Jr.; Alvin D. 3-(3-aryloxyphenyl)-1 (substituted methyl)-s-triazine-2,4,6-oxo or thiotrione herbicidal agents
US5679791A (en) 1996-07-25 1997-10-21 American Cyanamid Company 1-(3-heterocyclylphenyl)-s-triazine-2,4,6-oxo or thiotrione herbicidal agents
MXPA01003542A (es) 1998-10-08 2002-09-18 New Ace Res Company Composiciones y metodos nuevos para la prevencion y tratamiento de enfermedad causada por protozoarios.
AU2198100A (en) 1998-12-22 2000-07-12 Bayer Corporation Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma
DE19937500A1 (de) 1999-08-09 2001-02-15 Bayer Ag Substituierte Heterocyclylbenzofurane
DE19958388A1 (de) 1999-12-03 2001-06-07 Bayer Ag Triazinonverbindungen zur Behandlung von durch den Befall mit parasitischen Protozoen bedingten Krankheiten
US6444615B1 (en) 2000-04-18 2002-09-03 Dow Agrosciences Llc Herbicidal imidazolidinetrione and thioxo-imidazolidinediones
DE10034800A1 (de) 2000-07-18 2002-01-31 Bayer Ag Substituierte Benzostickstoffheterocyclen
DE10040174A1 (de) 2000-08-17 2002-02-28 Bayer Ag Verwendung von Triazintrion-Sulfonen zur Bekämpfung von Coccidiosen
DE10040110A1 (de) 2000-08-17 2002-02-28 Bayer Ag Verwendung von Triazintrion-Sulfoxiden zur Bekämpfung von Coccidiosen
AU2002324586B2 (en) 2001-08-02 2008-04-24 Neurocrine Biosciences, Inc. 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists
US6861523B2 (en) 2002-02-08 2005-03-01 Torrey Pines Institute For Molecular Studies 1,3,5- trisubstituted-1,3,5-triazine-2,4,6-trione compounds and libraries
WO2003101980A1 (en) 2002-05-30 2003-12-11 Solvay Pharmaceuticals B.V. 1,3,5-triazine derivatives as ligands for human adenosine-a3 receptors
US7241763B2 (en) 2002-07-15 2007-07-10 Janssen Pharmaceutica N.V. 3-furanyl analogs of toxoflavine as kinase inhibitors
DE102006038292A1 (de) 2006-08-16 2008-02-21 Bayer Healthcare Ag Transdermale Anwendung von Triazinen zur Bekämpfung von Coccidien-Infektionen
WO2008148008A1 (en) * 2007-05-23 2008-12-04 Emory University High throughput bioassay for identifying selective trka receptor agonists, and gambogic amide, a selective trka agonist with neuroprotective activity
US20120004310A1 (en) 2010-05-28 2012-01-05 Longo Frank M Non-peptide bdnf neurotrophin mimetics
RU2015141934A (ru) 2013-03-15 2017-04-20 Фарматрофикс, Инк. Непептидные миметики нейротрофина bdnf
MX2016008842A (es) 2014-01-20 2016-11-08 Hoffmann La Roche Derivados de n-fenil-lactama capaces de estimular la neurogenesis y su uso en el tratamiento de trastornos neurologicos.
MX387871B (es) 2014-12-10 2025-03-19 Mars Inc Metodos para modular los receptores del gusto.
JP2020502225A (ja) 2016-12-21 2020-01-23 アルゼキュア ファーマ アーべー トリアジントリオン誘導体、ならびにニューロトロフィン受容体および受容体型チロシンキナーゼのモジュレーターとしてのその使用。
MA52415A (fr) 2018-02-26 2021-01-06 AlzeCure Pharma AB Dérivés de triazine pour le traitement de maladies associées à des neurotrophines
GB201810669D0 (en) 2018-06-28 2018-08-15 Stiftelsen Alzecure New compounds
GB201912404D0 (en) 2019-08-29 2019-10-16 AlzeCure Pharma AB New compounds

Also Published As

Publication number Publication date
US20210371402A1 (en) 2021-12-02
CN112513032A (zh) 2021-03-16
CA3104237A1 (en) 2020-01-02
US11840524B2 (en) 2023-12-12
CN112513032B (zh) 2024-07-02
WO2020002950A1 (en) 2020-01-02
EP3814335A1 (en) 2021-05-05
KR20210024531A (ko) 2021-03-05
JP7510358B2 (ja) 2024-07-03
BR112020026619A2 (pt) 2021-03-30
EP3814335B1 (en) 2022-11-09
JP2021529168A (ja) 2021-10-28
ES2935183T3 (es) 2023-03-02

Similar Documents

Publication Publication Date Title
IL280609A (en) Pyrrolo-dipyridine compounds
GB201810092D0 (en) Compounds
GB201805174D0 (en) Compounds
GB201801355D0 (en) Compounds
GB201807924D0 (en) Compounds
GB201810581D0 (en) Compounds
GB201808093D0 (en) Compounds
GB201812382D0 (en) Compounds
GB201811169D0 (en) New compounds
GB201814151D0 (en) Compounds
GB201810668D0 (en) New compounds
GB201809102D0 (en) Compounds
GB201810669D0 (en) New compounds
GB201814167D0 (en) Compounds
GB201810071D0 (en) Compounds
GB201803340D0 (en) Compounds
GB201801128D0 (en) Compounds
GB201801130D0 (en) Compounds
GB201817634D0 (en) New compounds
GB201813681D0 (en) New compounds
GB201819102D0 (en) Compounds
GB201805945D0 (en) New compounds
GB201804745D0 (en) New compounds
GB201817342D0 (en) Compounds
GB201817303D0 (en) Compounds

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: ALZECURE PHARMA AB

Free format text: FORMER OWNER: STIFTELSEN ALZECURE

AT Applications terminated before publication under section 16(1)